If you’re struggling to manage your weight in San Antonio, TX, and traditional methods like diet and exercise haven’t brought the results you’re looking for, Retatrutide could be a breakthrough solution. At Injectco – PRP Treatment Clinic San Antonio, we offer physician-supervised Retatrutide weight loss injections through a compassionate, nurse-led program built on clinical excellence.
This advanced, triple-action peptide, developed by Eli Lilly, has demonstrated remarkable outcomes in clinical trials. According to research published in the New England Journal of Medicine, participants lost up to 24.2% of their body weight within 48 weeks. Our team supports you every step of the way. From personalized dosing plans to same-day prescription shipping.
We proudly support patients throughout Bexar County and beyond, including:
Our flexible telehealth options make it easy to begin treatment whether you live downtown, work at Joint Base San Antonio, or commute from Hill Country communities.
Many patients are familiar with GLP‑1 medications like Semaglutide (Ozempic®, Wegovy®) and Tirzepatide (Mounjaro®, Zepbound®). Retatrutide improves on these therapies by activating three key receptors involved in hunger, energy, and fat metabolism.
| Medication | GLP‑1 | GIP | Glucagon | Avg. Weight Loss (48 wks) |
|---|---|---|---|---|
| Semaglutide | ✅ | ❌ | ❌ | ~15% |
| Tirzepatide | ✅ | ✅ | ❌ | ~21% |
| Retatrutide | ✅ | ✅ | ✅ | ~24% |
This triple-action design helps overcome weight loss plateaus and addresses more than just appetite, it also boosts fat burning and metabolic stability.
Retatrutide mimics three naturally occurring gut hormones that regulate appetite, blood sugar, and energy use:
GLP‑1:
GIP:
Glucagon:
Together, these mechanisms help reset how your body manages food, hunger, and fat storage without triggering the intense hunger or fatigue many people face when dieting.
A pivotal study published in the New England Journal of Medicine (2023) followed 338 participants without diabetes. Results from the highest-dose Retatrutide group included:
These results were also featured at the American Diabetes Association’s 2023 Scientific Sessions and support Retatrutide’s role in metabolic health management.
Beyond the numbers, Retatrutide offers real-life advantages that San Antonio patients appreciate:
If you’ve plateaued on other GLP‑1 therapies, this next-generation medication may help move the needle again.
All consultations at Injectco San Antonio are free, whether you meet with us virtually or in person.
During your consult, we’ll:
If eligible, your order is placed the same day often with same-day shipping. You’ll leave your appointment with practical tools, including lifestyle tips to support success.
We take patient safety seriously. Here’s how we protect your health throughout the program:
You may be a good candidate if you:
We’ll verify eligibility during your consultation.
Initial consultation
Online or in person, with flexible hours
Health screening
Includes lab review and physician input
Personalized plan
Customized dose ramp-up schedule
Medication delivery
Discreet, cold-packed shipping to your door
Ongoing support
Monthly check-ins, adjustments, and coaching
Success isn’t just about medication. It’s about creating a healthier routine. Our team encourages patients to:
Want support with habit-building? We can help.
Most symptoms are temporary and fade with time:
We help you manage symptoms with hydration tips, gradual dosing, and check-ins.
Take the First Step. Schedule Your Free San Antonio Consultation Today.
Each plan includes:
Pricing depends on your dose and duration. We’ll walk you through everything after your consult. No surprises.
Retatrutide is being studied as an investigational metabolic therapy that targets multiple hormone pathways involved in appetite regulation, glucose balance, and energy use. In a supervised clinical setting, it may be incorporated into a structured medical weight management plan for eligible patients.
Treatment is individualized and overseen by licensed providers. The goal is steady, sustainable progress with medical monitoring rather than rapid, unsupervised weight loss.
Retatrutide is currently investigational and has not been approved by the FDA as a commercial weight loss medication. Access is typically provided through medically supervised programs that follow appropriate screening and compliance protocols.
A consultation is required to determine eligibility and review risks, benefits, and alternative treatment options.
Candidates are generally evaluated based on BMI, weight history, metabolic health indicators, and overall medical profile. Providers also review current medications, endocrine history, and prior experiences with weight loss therapies.
Eligibility is determined through individualized medical screening. Not every patient is a candidate, and recommendations are made based on clinical assessment.
Traditional diet plans focus primarily on calorie reduction and behavior changes. Retatrutide is designed to influence hormonal pathways that affect hunger, fullness, and metabolic signaling.
When combined with structured nutrition and activity guidance, it may support appetite regulation in a medically supervised environment. Individual results vary and are monitored over time.
The most frequently reported side effects are gastrointestinal, especially during early treatment or dose increases. These may include nausea, reduced appetite, constipation, reflux, or mild abdominal discomfort.
Providers typically use gradual dose titration and practical dietary strategies to help improve tolerance. Any persistent or severe symptoms should be discussed promptly.
Smaller meals, steady hydration, and consistent protein intake often improve comfort—particularly during dose adjustments. Avoiding heavy or high-fat meals early in treatment may also reduce nausea.
Providers emphasize sustainable nutrition habits rather than extreme dieting. Comfort and consistency are priorities.
Depending on your health history and risk factors, baseline lab work may be recommended. Labs can help establish a safety baseline and guide monitoring during treatment.
Your provider will determine what testing is appropriate based on your clinical profile and overall health.
Follow-ups are typically more frequent during the initial titration phase to evaluate tolerance, appetite changes, and weight trends. Once dosing stabilizes, visit frequency may be adjusted.
Ongoing monitoring supports safety, responsible prescribing, and sustainable outcomes.
All current prescriptions, supplements, and medical conditions must be reviewed before starting treatment. Providers carefully evaluate potential interactions and safety considerations.
Combination therapy decisions are made on an individual basis and only when clinically appropriate.
The first step is scheduling a medical consultation with a licensed provider. Your health history, medications, goals, and eligibility will be reviewed, and labs may be recommended if clinically indicated.
If appropriate, you’ll receive a personalized treatment plan with dosing guidance and structured follow-ups. Care is provided under medical supervision with informed consent and patient education.
